李佳玉,周力,陈晖

• 1:首都医科大学附属北京友谊医院心脏中心

摘要(Abstract)：

<正>心血管疾病(cardiavascular disease,CVD)和癌症虽然是两种不同的疾病,但具有显著的共性,包括危险因素、遗传、代谢和炎症成分,以及一些预防策略,是目前世界范围内导致死亡的两个主要原因。预计到2030年,全球每年将有2360万新发的癌症病例,且癌症幸存者的数量急剧增加,其中大多是在高龄、新出现的或已存在CVD和危险因素的情况下[1]。不同的癌症治疗方法,包括化疗、免疫疗法、放射疗法和靶向疗法,不仅影响癌细胞,还影响心肌细胞,挑战着心血管系统。根据2016年欧洲心脏病学会(European Society of Cardiology,ESC)关于癌症治疗和心血管毒性的立场文件,癌症患者的心血管并发症分为九大类:心肌功能障碍和心力

关键词(KeyWords)： 肿瘤心脏病学;心血管疾病;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李佳玉,周力,陈晖

参考文献(References)：

• [1]Lancellotti P,Suter TM,López-Fernández T,et al.Cardio-oncology services:rationale,organization,and implementation.Eur Heart J,2019,40(22):1756-1763.
• [2]Zamorano JL,Lancellotti P,Rodriguez Mu?oz D,et al.2016ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines:the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology(ESC).Eur J Heart Fail,2017,19(1):9-42.
• [3]Liu Y,Zhang YL,Liu JW,et al.Emergence,development,and future of cardio-oncology in China.Chin Med J(Engl),2018,131(21):2640-2644.
• [4]Curigliano G,Cardinale D,Dent S,et al.Cardiotoxicity of anticancer treatments:Epidemiology,detection,and management.CA Cancer JClin,2016,66(4):309-325.
• [5]Risk of cardiovascular disease among nordic childhood cancer survivors with diabetes mellitus:A report from adult life after childhood cancer in Scandinavia.Cancer,2018,124(22):4393-4400.
• [6]Rassaf T,Totzeck M.Modern concepts in cardio-oncology.J Thorac Dis,2018,10(Suppl 35):S4386-S4390.
• [7]Aschermann M.Prevention of arterial and venous thrombosis in cancer patients.Cor et Vasa,2013,55(2):e196-e200.
• [8]Onwudiwe NC,Kwok Y,Onukwugha E,et al.Cardiovascular eventfree survival after adjuvant radiation therapy in breast cancer patients stratified by cardiovascular risk.Cancer Med,2014,3(5):1342-1352.
• [9]Michel L,Rassaf T,Totzeck M.Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity.JThoracic Dis,2018,10(Suppl 35):S4282-S4295.
• [10]Donnellan E,Phelan D,Mccarthy CP,et al.Radiation-induced heart disease:A practical guide to diagnosis and management.Clevel Clin J Med,2016,83(12):914-922.
• [11]Di Maggio FM,Minafra L,Forte GI,et al.Portrait of inflammatory response to ionizing radiation treatment.J Inflam(Lond),2015,12:14.
• [12]Wang Y,Boerma M,Zhou D.Ionizing radiation-induced endothelial cell senescence and cardiovascular diseases.Radiat Res,2016,186(2):153-161.
• [13]Saiki H,Petersen,IA,Scott CG,et al.Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer.Circulation,2017,135(15):1388-1396.
• [14]Chang HM,Moudgil R,Scarabelli T,et al.Cardiovascular complications of cancer therapy:Best practices in diagnosis,prevention,and management:Part 1.J Am Coll Cardiol,2017,70(20):2536-2551.
• [15]Haugnes HS,Wethal T,Aass N,et al.Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer:a 20-year follow-up study.J Clin Oncol,2010,28(30):4649-4657.
• [16]Totzeck M,Mincu RI,Rassaf T.Cardiovascular adverse events in patients with cancer treated with bevacizumab:A Meta‐analysis of more than 20 000 patients.J Am Heart Assoc,2017,6(8):e006278.
• [17]Totzeck M,Mincu RI,Mrotzek S,et al.Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity:A Meta-analysis of approximately 29 000cancer patients.Eur J Prev Cardiol,2018,25(5):482-494.
• [18]Chang HM,Okwuosa TM,Scarabelli T,et al.Cardiovascular complications of cancer therapy:best practices in diagnosis,prevention,and management:Part 2.J Am Coll Cardiol,2017,70(20):2536-2551.
• [19]Kristinsson SY.Thrombosis in multiple myeloma.Hematology Am Soc Hematol Educ Program,2010:437-444.
• [20]Yusuf SW,Daraban N,Abbasi N,et al.Treatment and outcomes of acute coronary syndrome in the cancer population.Clin Cardiol,2012,35(7):443-450.
• [21]Nishimura RA,Otto CM,Bonow RO,et al.2014 AHA/ACCguideline for the management of patients with valvular heart disease:A report of the American College of Cardiology/American Heart Association task f orce on practice guidelines.J Thorac Cardiovasc Surg,2014,148(1):e1-e132.
• [22]Roffi M,Patrono C,Collet JP,et al.2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:task f orce f or the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC).Eur Heart J,2016,37(3):267-315.
• [23]Iliescu C,Grines CL,Herrmann J,et al.SCAI Expert consensus statement:Evaluation,management,and special considerations of cardio-oncology patients in the cardiac catheterization laboratory(endorsed by the cardiological society of india,and sociedad Latino Americana de Cardiolog?a Intervencionista.Catheter Cardiovasc Interv,2016,87(5):895-899.
• [24]Potts JE,Iliescu CA,Lopez Mattei JC,et al.Percutaneous coronary intervention in cancer patients:a report of the prevalence and outcomes in the United States.Eur Heart J,2019,40(22):1790-1800.
• [25]Tabata N,Sueta D,Yamamoto E,et al.Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention:a Kumamoto University Malignancy and Atherosclerosis(KUMA)study.Eur Heart J Qual Care Clin Outcomes,2018,4(4):290-300.
• [26]Tabata N,Sueta D,Yamamoto E,et al.A retrospective study of arterial stiffness and subsequent clinical outcomes in cancer patients undergoing percutaneous coronary intervention.J Hypertens,2019,37(4):754-764.
• [27]Guddati AK,Joy PS,Kumar G.Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period.J Cancer Res Clin Oncol,2016,142(2):471-479.
• [28]Patel MR,Dehmer GJ,Hirshfeld JW,et al.ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update:A report of the American College of Cardiology Foundation appropriate use criteria task force,Society for Cardiovascular Angiography and Interventions,Society of Thoracic Surgeons,American Association for Thoracic Surgery,American Heart Association,American Society of Nuclear Cardiology,and the Society of Cardiovascular Computed Tomography.J Am Coll Cardiol,2012,59(9):857-881.
• [29]Velders MA,Boden H,Hofma SH,et al.Outcome after STelevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention.Am J Cardiol,2013,112(12):1867-1872.
• [30]Arslan F,Bongartz L,Ten Berg JM,et al.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:comments from the Dutch ACS woking group.Neth Heart J,2018,26(9):417-421.
• [31]Elting LS,Rubenstein EB,Martin CG,et al.Incidence,cost,and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia.JClin Oncol,2001,19(4):1137-1146.
• [32]Lo TS,Ratib K,Chong AY,et al.Impact of access site selection and operator expertise on radiation exposure;a controlled prospective study.Am Heart J,2012,164(4):455-461.
• [33]Kok MM,Weernink MGM,Birgelen CV,et al.Patient preference for radial versus femoral vascular access for elective coronary procedures:The PREVAS study.Catheter Cardiovasc Interv,2018,91(1):17-24.
• [34]Levine GN,Bates ER,Bittl JA,et al.2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.J Am Coll Cardiol,2016,68(10):1082-1115.
• [35]Zhang D,Lv S,Song X,et al.Fractional flow reserve versus angiography for guiding percutaneous coronary intervention:a meta-analysis.Heart,2015,101(6):455-462.
• [36]Sen S,Escaned J,Malik IS,et al.Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis:results of the ADVISE(ADenosine Vasodilator Independent Stenosis Evaluation)study.J Am Coll Cardiol,2012,59(15):1392-1402.
• [37]Petraco R,Park JJ,Sen S,et al.Hybrid i FR-FFR decisionmaking strategy:implications for enhancing universal adoption of physiology-guided coronary revascularization.Euro Intervention,2013,8(10):1157-1165.
• [38]G?tberg M,Cook CM,Sen S,et al.The evolving future of instantaneous wave-free ratio and fractional flow reserve.J Am Coll Cardiol,2017,70(11):1379-1402.
• [39]Liu VY,Agha AM,Lopez-Mattei J,et al.Interventional cardiooncology:adding a new dimension to the cardio-oncology field.Front Cardiovasc Med,2018,5:48.
• [40]Mintz GS,Guagliumi G.Intravascular imaging in coronary artery disease.Lancet,2017,390(10096):793-809.
• [41]Sonoda S,Hibi K,Okura H,et al.Current clinical use of intravascular ultrasound imaging to guide percutaneous coronary interventions.Cardiovasc Interv Ther,2020,35(1):30-36.
• [42]Berger PB,Kleiman NS,Pencina MJ,et al.Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement:results from the EVENT(Evaluation of Drug-Eluting Stents and Ischemic Events)registry.JACCCardiovasc Interv,2010,3(9):920-927.
• [43]Piccolo R,Feres F,Abizaid A,et al.Risk of early adverse events after clopidogrel discontinuation in patients undergoing short-term dual antiplatelet therapy:an individual participant data analysis.JACC Cardiovasc Interv,2017,10(16):1621-1630.
• [44]Navi BB,Reiner AS,Kamel H,et al.Risk of arterial thromboembolism in patients with cancer.J Am Coll Cardiol,2017,70(8):926-938.
• [45]Iliescu CA,Cilingiroglu M,Giza DE,et al.“Bringing on the light”in a complex clinical scenario-Optical coherence tomographyguided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease(PROTECT-OCT registry).Am Heart J,2017,194:83-91.
• [46]李占鲁，王敏，栾毅，等.Se Quent Please药物涂层球囊扩张术治疗冠状动脉粥样硬化性心脏病患者临床预后的回顾性分析.中国介入心脏病学杂志，2019,27(7):380-385.
• [47]von Zur Mühlen C,Reiss S,Krafft AJ,et al.Coronary magnetic resonance imaging af ter routine implantation of bioresorbable vascular scaffolds allows non-invasive evaluation of vascular patency.PLo S One,2018,13(1):e0191413.
• [48]张立博，邓婧，魏向龙.生物可吸收支架在急性冠状动脉综合征中应用的Meta分析.中国介入心脏病学杂志，2018,26(7):390-399.
• [49]Kurlansky P,Herbert M,Prince S,et al.Coronary artery bypass graft versus percutaneous coronary intervention:meds matter:impact of adherence to medical therapy on comparative outcomes.Circulation,2016,134(17):1238-1246.
• [50]Assali A,Vaknin-Assa,Lev E,et al.The risk of cardiac complications following noncardiac surgery in patients with drug eluting stents implanted at least six months before surgery.Catheter Cardiovasc Interv,2009,74(6):837-843.